Hims & Hers Health, Inc. $HIMS Shares Bought by FirstWave Capital Management LLC

FirstWave Capital Management LLC raised its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 30.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 339,978 shares of the company’s stock after acquiring an additional 79,731 shares during the period. Hims & Hers Health makes up 5.2% of FirstWave Capital Management LLC’s holdings, making the stock its 5th largest position. FirstWave Capital Management LLC owned 0.15% of Hims & Hers Health worth $11,787,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. State Street Corp lifted its holdings in Hims & Hers Health by 1.8% during the fourth quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after acquiring an additional 132,311 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Hims & Hers Health by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after acquiring an additional 608,950 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Hims & Hers Health by 194.4% in the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock worth $90,465,000 after acquiring an additional 2,877,550 shares in the last quarter. Invesco Ltd. raised its position in shares of Hims & Hers Health by 62.7% during the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after purchasing an additional 1,600,004 shares during the period. Finally, Marex Group plc lifted its holdings in shares of Hims & Hers Health by 162.2% during the 4th quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock valued at $78,562,000 after purchasing an additional 1,496,707 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers continues to show strong top-line momentum: second-quarter revenue rose 38.2% year over year to $753.2 million and exceeded analyst expectations. The company also raised its 2026 revenue outlook, supported by weight-loss treatments, international expansion and artificial-intelligence initiatives. HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
• Neutral Sentiment: Analyst sentiment remains cautious. The consensus rating is “Hold,” with analysts recognizing the company’s growth opportunities while citing profitability pressure and uncertainty related to regulatory oversight.
• Negative Sentiment: Several investor-rights firms announced or promoted a securities-fraud class action against Hims & Hers and certain executives. The case covers investors who acquired securities between August 4, 2025, and July 29, 2026; investors must move for lead-plaintiff status by November 2, 2026. The repeated announcements increase concerns about potential legal expenses, penalties, management distraction and reputational damage. Rosen Law Firm HIMS Class Action Announcement
• Negative Sentiment: The litigation is tied to allegations stemming from an FTC complaint, including potentially deceptive privacy and billing practices. Claims that consumer health information may have been shared with advertising platforms and that customers may have been charged soon after submitting prescription-intake forms create risks of enforcement actions and additional compliance costs. These claims remain allegations. Kessler Topaz HIMS Investor Alert
• Negative Sentiment: Insider Soleil Boughton sold 3,458 shares for approximately $98,000 under a pre-arranged Rule 10b5-1 trading plan. The transaction reduced the insider’s holdings by about 1.1%, making it a relatively small and scheduled sale, but it adds a modest negative signal amid the broader legal uncertainty. Hims & Hers Insider Sale

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 4,938 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $29.99, for a total transaction of $148,090.62. Following the completion of the sale, the chief financial officer owned 264,117 shares of the company’s stock, valued at $7,920,868.83. This represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total value of $441,850.50. Following the completion of the transaction, the chief operating officer owned 432,124 shares in the company, valued at approximately $13,611,906. The trade was a 3.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 190,227 shares of company stock valued at $6,133,613 in the last quarter. Corporate insiders own 11.76% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on HIMS shares. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. UBS Group set a $23.00 target price on shares of Hims & Hers Health in a research note on Friday, May 22nd. Jefferies Financial Group set a $24.50 target price on Hims & Hers Health in a report on Tuesday, May 12th. Finally, Bank of America lifted their price target on Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $32.50.

Hims & Hers Health Stock Down 0.6%

Hims & Hers Health stock opened at $27.66 on Friday. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The company’s 50-day moving average is $31.67 and its 200-day moving average is $26.75. The firm has a market capitalization of $6.45 billion, a PE ratio of -43.90 and a beta of 2.42. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $65.30.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. During the same period in the prior year, the business earned $0.17 EPS. The company’s revenue for the quarter was up 38.2% compared to the same quarter last year.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.